Who makes Healive® Lot 2?

Healive® Lot 2 is developed by Sinovac Biotech Co., Ltd.

What development phase is Healive® Lot 2 in?

Healive® Lot 2 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Healive® Lot 2

Sinovac Biotech Co., Ltd · FDA-approved active Biologic Quality 2/100

Healive® Lot 2, marketed by Sinovac Biotech Co., Ltd, is a pharmaceutical product with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging Sinovac's established reputation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	Healive® Lot 2
Sponsor	Sinovac Biotech Co., Ltd
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Healive® Lot 2 CI brief — competitive landscape report
Healive® Lot 2 updates RSS · CI watch RSS
Sinovac Biotech Co., Ltd portfolio CI